Entrada Therapeutics (TRDA) Change in Acquisitions & Divestments (2022 - 2026)

Entrada Therapeutics' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $38.9 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 54.79% year-over-year to $38.9 million in Q1 2026; TTM through Mar 2026 was $212.4 million, a 43.38% decrease from a year earlier, with the FY2025 full-year figure at $259.5 million, down 37.19% from the prior year.
• Change in Acquisitions & Divestments fell to $38.9 million in Q1 2026 per TRDA's latest filing, from $47.4 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $123.9 million in Q1 2024 and bottomed at $1.7 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $63.0 million (2023), against an average of $62.5 million.
• Across the five-year window, Change in Acquisitions & Divestments jumped 3575.61% in 2023 and tumbled 60.01% in 2025, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $19.5 million in 2022, then surged by 456.62% to $108.5 million in 2023, then gained by 9.17% to $118.5 million in 2024, then tumbled by 60.01% to $47.4 million in 2025, then dropped by 18.0% to $38.9 million in 2026.
• Per Business Quant, the three latest TRDA Change in Acquisitions & Divestments figures stand at $38.9 million (Q1 2026), $47.4 million (Q4 2025), and $75.5 million (Q3 2025).